EBF1-induced CSRP2 boosts the progression of B-cell acute lymphocytic leukemia by inhibiting ferroptosis
Cancer Letters · 2025-04 · 614 · 217556
DOI: 10.1016/j.canlet.2025.217556 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2025-04. Verfasst von Chengcheng Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The Third Affiliated Hospital of Sun Yat-Sen University, Sun Yat-Sen Institute of Hematology, Guangzhou, Guangdong, 510630,…. Hauptthemen laut MEDLINE: Ferroptosis, Trans-Activators, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Natural Science Foundation of Guangdong Province, Basic and Applied Basic Research Foundation of Guangdong Province.
Abstract (Originalsprache)
B-cell acute lymphocytic leukemia (B-ALL) is a highly aggressive malignancy with poor prognosis. Developing diagnostic markers and therapeutic targets to identify and treat B-ALL early would improve the outcomes of B-ALL patients. Here, we conducted RNA next-generation sequencing using bone marrow (BM) specimens obtained from 7 B-ALL patients and 7 healthy donors. We found cysteine and glycine-rich protein 2 (CSRP2) upregulated in B-ALL. Down-regulation of CSRP2 resulted in suppressed cell proliferation and enhanced cell apoptosis in B-ALL. In addition, inhibition of CSRP2 increased cell ferroptosis in B-ALL cells. Mechanically, we revealed that transcription factor early B cell factor 1 (EBF1) regulated CSRP2 levels in B-ALL, and inhibition of EBF1 decreased CSRP2 levels in B-ALL. In conclusion, the dysregulation EBF1 led to CSRP2 upregulation and resulting in progression of B-ALL. The EBF1/CSRP2 axis could be of great potential as therapeutic targets for B-ALL treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, The Third Affiliated Hospital of Sun Yat-Sen University, Sun Yat-Sen Institute of Hematology, Guangzhou, Guangdong, 510630, PR China.
- Institute of Hematology, Jinan University, Guangzhou, Guangdong, 510632, PR China.
- Department of Hematology, The Third Affiliated Hospital of Sun Yat-Sen University, Sun Yat-Sen Institute of Hematology, Guangzhou, Guangdong, 510630, PR China; Institute of Hematology, Jinan University, Guangzhou, Guang…
- Department of Interventional Radiology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, 510630, PR China.
- State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, PR China. Electronic address: tanghl@sysucc.org.cn.
- State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, PR China. Electronic address: wanghua@sysucc.org.cn.
Förderung
- Natural Science Foundation of Guangdong Province
- Basic and Applied Basic Research Foundation of Guangdong Province
Zitieren
APA
Liu, C., Liu, G., Zhou, F., Chen, L., Chang, B., Tang, H., & Wang, H. (2025). EBF1-induced CSRP2 boosts the progression of B-cell acute lymphocytic leukemia by inhibiting ferroptosis. Cancer Letters, 614, 217556. https://doi.org/10.1016/j.canlet.2025.217556
Vancouver
Liu C, Liu G, Zhou F, Chen L, Chang B, Tang H, et al. EBF1-induced CSRP2 boosts the progression of B-cell acute lymphocytic leukemia by inhibiting ferroptosis. Cancer Letters. 2025;614:217556. doi:10.1016/j.canlet.2025.217556
BibTeX
@article{Liu2025,
author = {Liu, Chengcheng and Liu, Gexiu and Zhou, Fenling and Chen, Lu and Chang, Boyang and Tang, Hailin and Wang, Hua},
title = {EBF1-induced CSRP2 boosts the progression of B-cell acute lymphocytic leukemia by inhibiting ferroptosis},
journal = {Cancer Letters},
year = {2025},
volume = {614},
pages = {217556},
doi = {10.1016/j.canlet.2025.217556}
}
EUVIMED